Phaseline

Companies › Halia Therapeutics

Halia Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Neurology, Hematology; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HT-4253–Phase 2Alzheimers DiseaseFeb 2028
HT-6184
CD71 transferrin receptor antagonist
TFRCPhase 2Myelodysplastic Syndrome–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07052006HT-6184Phase 2Myelodysplastic SyndromeHematologyJan 2026
NCT07399171HT-4253Phase 2Alzheimers DiseaseNeurologyFeb 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

TFRC (1)

Companies with the same targets

JCR Pharmaceuticals

Companies built like this

Nuvig Therapeutics Biossil Actinogen Medical Abrexa Pharmaceuticals Imara

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.